Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Sareum submits cancer trial application

The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum.
Sareum submits cancer trial application
Two clinical trials in cancer patients are planned.

Drug developer Sareum (LON:SAR) has submitted its application for two Phase I clinical trials of CHK1 inhibitor CCT245737  to the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum. 

Two clinical trials in cancer patients are planned. One will use CCT245737 as a single anti-cancer agent and the other in combination with standard-of-care chemotherapy.

Once approval is obtained, these trials will be funded in collaboration with co-development partner, the CRT Pioneer Fund.

Sareum has put up £797,500 of development funding so far.

Tim Mitchell, chief executive, said it was a further significant step towards the planned clinical trials with cancer patients.

Checkpoint Kinase 1 (CHK1)  helps control the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage. 

PhilW.jpg
Why Invest In Sareum Holdings Plc? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile

Sareum Holdings Plc Timeline

Big Picture
February 20 2017

Related Articles

Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use